24518-2018 - Competition

Pre–commercial procurement (PCP) to buy R&D (research & development) services to improve the treatment and self-management of diabetes type 2 patients using a Personalised Diabetes Management Solution

This contract notice invites interested operators to submit tenders to a procurement.

The procurement aims to trigger new solutions to be developed and tested to address the challenge of providing more effective management of diabetes type2 patients tackling the rising incidence rate of diabetes through a personalised diabetes management solution.

The main areas to be addressed are: person-centred care, personalised care: multi-disciplinary care, early detection, personalised decision support, self-management support, self-help and peer support, a learning healthcare system, interoperability and integration.

More information can be found on the ProEmpower website: http://proempower-pcp.eu/

This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

Main site or place of performance: Testing is expected to take place in Amadora, PT; Murcia, ES, Naples, IT and Istanbul, TR. At least 50 % of the contracted R&D services must be in EU Member States or Horizon 2020 associated countries.

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions. Each selected operator will be awarded a framework agreement that covers three R&D phases. The three phases are: solution design, prototyping, original development, and validation and testing of a limited set of first products or services. After each phase, intermediate evaluations will be carried out to select the best of the competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase.

The procurement is expected to start in May 2018 and end in March 2020.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions i.e. beyond the procurers.

This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs.

Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation.

The open procedure was chosen for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures.

Tenders must be submitted in English. Deliverables must be submitted in English. The PCP language is English and the framework agreement and the specific phase contract must be signed in the English version. Communication (relating to either the tender procedure or the implementation of the contract) must be carried out in English. For field testing in phase 3 the ability to speak the local languages (Spanish, Italian, Turkish and Portuguese) will be an advantage.

This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them.

List and brief description of conditions:

For further information please read the procurement documents.

Electronic payment will be used

Precise information on deadline(s) for review procedures: